PURPOSE: Fundamental gaps in knowledge regarding the risk of subsequent neoplasms (SNs) in children with pathogenic neurofibromatosis type 1 (NF1) variants exposed to radiation and/or alkylator chemotherapy have limited the use of these agents. METHODS: We addressed these gaps by determining the SN risk in 167 NF1-affected versus 1,541 non-NF1-affected 5-year childhood cancer survivors from the Childhood Cancer Survivor Study and 176 nonoverlapping NF1-affected individuals with primary tumors from University of Alabama at Birmingham and Children's Hospital of Philadelphia exposed to radiation and/or chemotherapy. Proportional subdistribution hazards multivariable regression analysis was used to examine risk factors, adjusting for type and age at primary tumor diagnosis and therapeutic exposures. RESULTS: In the Childhood Cancer Survivor Study cohort, the 20-year cumulative incidence of SNs in NF1 childhood cancer survivors was 7.3%, compared with 2.9% in the non-NF1 childhood cancer survivors (P = .003), yielding a 2.4-fold higher risk of SN (95% CI, 1.3 to 4.3; P = .005) in the NF1-affected individuals. In the University of Alabama at Birmingham and Children's Hospital of Philadelphia cohort, among NF1-affected individuals with a primary tumor, the risk of SNs was 2.8-fold higher in patients with irradiated NF1 (95% CI, 1.3 to 6.0; P = .009). In contrast, the risk of SNs was not significantly elevated after exposure to alkylating agents (hazard ratio, 1.27; 95% CI, 0.3 to 3.0; P = .9). CONCLUSION: Children with NF1 who develop a primary tumor are at increased risk of SN when compared with non-NF1 childhood cancer survivors. Among NF1-affected children with a primary tumor, therapeutic radiation, but not alkylating agents, confer an increased risk of SNs. These findings can inform evidence-based clinical management of primary tumors in NF1-affected children.
PURPOSE: Fundamental gaps in knowledge regarding the risk of subsequent neoplasms (SNs) in children with pathogenic neurofibromatosis type 1 (NF1) variants exposed to radiation and/or alkylator chemotherapy have limited the use of these agents. METHODS: We addressed these gaps by determining the SN risk in 167 NF1-affected versus 1,541 non-NF1-affected 5-year childhood cancer survivors from the Childhood Cancer Survivor Study and 176 nonoverlapping NF1-affected individuals with primary tumors from University of Alabama at Birmingham and Children's Hospital of Philadelphia exposed to radiation and/or chemotherapy. Proportional subdistribution hazards multivariable regression analysis was used to examine risk factors, adjusting for type and age at primary tumor diagnosis and therapeutic exposures. RESULTS: In the Childhood Cancer Survivor Study cohort, the 20-year cumulative incidence of SNs in NF1 childhood cancer survivors was 7.3%, compared with 2.9% in the non-NF1 childhood cancer survivors (P = .003), yielding a 2.4-fold higher risk of SN (95% CI, 1.3 to 4.3; P = .005) in the NF1-affected individuals. In the University of Alabama at Birmingham and Children's Hospital of Philadelphia cohort, among NF1-affected individuals with a primary tumor, the risk of SNs was 2.8-fold higher in patients with irradiated NF1 (95% CI, 1.3 to 6.0; P = .009). In contrast, the risk of SNs was not significantly elevated after exposure to alkylating agents (hazard ratio, 1.27; 95% CI, 0.3 to 3.0; P = .9). CONCLUSION:Children with NF1 who develop a primary tumor are at increased risk of SN when compared with non-NF1 childhood cancer survivors. Among NF1-affected children with a primary tumor, therapeutic radiation, but not alkylating agents, confer an increased risk of SNs. These findings can inform evidence-based clinical management of primary tumors in NF1-affected children.
Authors: Saba Sharif; Rosalie Ferner; Jillian M Birch; James E Gillespie; H Rao Gattamaneni; Michael E Baser; D Gareth R Evans Journal: J Clin Oncol Date: 2006-06-01 Impact factor: 44.544
Authors: J M Maris; S R Wiersma; N Mahgoub; P Thompson; R J Geyer; C G Hurwitz; B J Lange; K M Shannon Journal: Cancer Date: 1997-04-01 Impact factor: 6.860
Authors: Leslie L Robison; Gregory T Armstrong; John D Boice; Eric J Chow; Stella M Davies; Sarah S Donaldson; Daniel M Green; Sue Hammond; Anna T Meadows; Ann C Mertens; John J Mulvihill; Paul C Nathan; Joseph P Neglia; Roger J Packer; Preetha Rajaraman; Charles A Sklar; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Debra L Friedman; John Whitton; Wendy Leisenring; Ann C Mertens; Sue Hammond; Marilyn Stovall; Sarah S Donaldson; Anna T Meadows; Leslie L Robison; Joseph P Neglia Journal: J Natl Cancer Inst Date: 2010-07-15 Impact factor: 11.816
Authors: Joseph P Neglia; Leslie L Robison; Marilyn Stovall; Yan Liu; Roger J Packer; Sue Hammond; Yutaka Yasui; Catherine E Kasper; Ann C Mertens; Sarah S Donaldson; Anna T Meadows; Peter D Inskip Journal: J Natl Cancer Inst Date: 2006-11-01 Impact factor: 11.816
Authors: George-Sorin Tiplica; Klaus Fritz; Alexandra Irina Butacu; Loredana Ungureanu; Carmen Maria Sălăvăstru Journal: Hautarzt Date: 2022-01-25 Impact factor: 0.751
Authors: Mina Lobbous; Joshua D Bernstock; Elizabeth Coffee; Gregory K Friedman; Laura K Metrock; Gustavo Chagoya; Galal Elsayed; Ichiro Nakano; James R Hackney; Bruce R Korf; Louis B Nabors Journal: Cancers (Basel) Date: 2020-01-01 Impact factor: 6.639
Authors: Peter de Blank; Nan Li; Michael J Fisher; Nicole J Ullrich; Smita Bhatia; Yutaka Yasui; Charles A Sklar; Wendy Leisenring; Rebecca Howell; Kevin Oeffinger; Kristina Hardy; M Fatih Okcu; Todd M Gibson; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: Genet Med Date: 2020-06-23 Impact factor: 8.864
Authors: Danny Laurent; Abbi E Smith; Waylan K Bessler; Marc Mendonca; Helen Chin-Sinex; Martina Descovich; Andrew E Horvai; D Wade Clapp; Jean L Nakamura Journal: Neurooncol Adv Date: 2021-04-23